PAPER So PP, Zeldich E, Seyb KI, Huang MM, Concannon JB, King GD, Chen CD, Cuny GD, Glicksman MA, Abraham CR

Lowering of amyloid beta peptide production with a small molecule inhibitor of amyloid-β precursor protein dimerization.

Am J Neurodegener Dis. 2012 May 30;1(1):75-87. PubMed: 22822474

PAPER Colom-Cadena M, Gelpi E, Martí MJ, Charif S, Dols-Icardo O, Blesa R, Clarimón J, Lleó A

MAPT H1 haplotype is associated with enhanced α-synuclein deposition in dementia with Lewy bodies.

Neurobiol Aging. 2012 Jul 20; PubMed: 22819391

PAPER Cruchaga C, Kauwe JS, Nowotny P, Bales K, Pickering EH, Mayo K, Bertelsen S, Hinrichs A, Alzheimer's Disease Neuroimaging Initiative, Fagan AM, Holtzman DM, Morris JC, Goate AM

Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease.

Hum Mol Genet. 2012 Oct 15;21(20):4558-71. Epub 2012 Jul 20 PubMed: 22821396

PAPER Darlington D, Deng J, Giunta B, Hou H, Sanberg CD, Kuzmin-Nichols N, Zhou HD, Mori T, Ehrhart J, Sanberg PR, Tan J

Multiple Low-Dose Infusions of Human Umbilical Cord Blood Cells Improve Cognitive Impairments and Reduce Amyloid-β-Associated Neuropathology in Alzheimer Mice.

Stem Cells Dev. 2012 Sep 5; PubMed: 22816379

PAPER Yassine N, Lazaris A, Dorner-Ciossek C, Després O, Meyer L, Maitre M, Mensah-Nyagan AG, Cassel JC, Mathis C

Detecting spatial memory deficits beyond blindness in tg2576 Alzheimer mice.

Neurobiol Aging. 2012 Jul 19; PubMed: 22819136

PAPER Noël S, Perez F, Pedersen JT, Alies B, Ladeira S, Sayen S, Guillon E, Gras E, Hureau C

A new water-soluble Cu(II) chelator that retrieves Cu from Cu(amyloid-β) species, stops associated ROS production and prevents Cu(II)-induced Aβ aggregation.

J Inorg Biochem. 2012 Jun 7; PubMed: 22819647

PAPER Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, Wisniewski T, Gunther EC, Strittmatter SM

Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons.

Nat Neurosci. 2012 Sep;15(9):1227-35. Epub 2012 Jul 22 PubMed: 22820466

Lon S. Schneider on No Pony in There: Bapi Fails Mild to Moderate ApoE4 Carriers

COMMENT The topline results of the Phase 3, bapineuzumab trial 302 are disappointing but not surprising. That is mainly because the prior Phase 2, 201 trial was a multiple ascending dose trial, not planned as an efficacy trial, and didn’t show reliable efficacy e

PAPER Pica-Mendez AM, Tanen M, Dallob A, Tanaka W, Laterza OF

Nonspecific binding of Aβ42 to polypropylene tubes and the effect of Tween-20.

Clin Chim Acta. 2010 Nov 11;411(21-22):1833. PubMed: 20655889

Heather Gray

United States

Rafal Smigrodzki

United States

Trent Nichols on Stockholm: Therapeutics Roundup—Some New, Some Not So Much

COMMENT A very important B study, but one lacking a methyl donor with the B6, folate, and B12. Unfortunately, the majority of therapeutic trials of the B vitamin ignore methyltetrahydrofolate reductase deficiency as a subgroup of Alzheimer's, which would be

Sanjay Pimplikar on Protective APP Mutation Found—Supports Amyloid Hypothesis

COMMENT This study provides elegant genetic evidence that reducing the BACE processing of APP protects against late-onset AD. The finding complements the long-standing observations that increased BACE processing (APPswe mutation or elevated BACE levels [1]) enhan

Yusheng Duan on Reversible mechanical unzipping of amyloid beta-fibrils.

COMMENT Good paper! 0 eeaduan

New Assays for Aβ Oligomers in CSF Claim Femtogram Sensitivity

CONFERENCE COVERAGE 2012-07-24 Conference Coverage The going hypothesis on amyloid-β forms states that oligomers are the most toxic species, and yet no one can robustly measure them in human CSF, where oligomers are rare clumps floating in a sea of monomer abundance. If researchers cou